Kornimate/medical-research-clean huggingface dataset:
study of residuals deformities after diaphyseal femoral fracture in children treated by skin traction

Conditions: EOS

Summary: diaphyseal femoral fracture in children \<6 years old are treated by the skin traction technique. as demonstrated by numerous studies, given the significant potential for bone remodeling in young children, remodeling (excluding rotational disorder) allows anatomical correction. the aim of this study is to confirm, via eos imaging, the absence of residual deformities 3 years after the end of treatment in children treated in amiens hospital department.


Eligibility criteria:
inclusion criteria: * \<6 years old at the time of the fracture * treatment by skin zenith traction * femoral shaft fracture, traumatic, unilateral exclusion criteria: * multiple fracture * pathological fracture * history of lower limb fracture * contraindication to zenith traction

Keywords: eos skin traction femoral fracture remodeling leg length
treating hypertension with breath control

Conditions: Hypertension

Summary: the purpose of this study is to determine if blood pressure can be reduced in hypertensive subjects by regularising and slowing their breathing. this may be a safe and affordable complementary treatment for hypertension.

this is a randomised controlled trial in which hypertensive subjects allocated to receive either a cd with relaxation music or one with the same music plus certain sound cues to guide the listener on when to breathe. the subjects will continue with their normal medications and the intervention will last 2 months.

Eligibility criteria:
inclusion criteria: * above 18 years old * patients with essential hypertension * systolic bp from 140 to 159 mm hg * diastolic bp from 90 to 99 mm hg * on hypertensive medication for at least 3 months before the study * hypertensive medication unchanged during the 3 months before the study * patients able to fill in a log sheet exclusion criteria: * ischaemic heart disease * congestive heart failure * cardiac arrhythmias * renal failure * diabetes mellitus * previous stroke * major organ failure * cigarette smoking * respiratory diseases * psychiatric disorders * severe obesity (bmi \>35 kg/m2) * hearing impairment * unable to operate a cd player or do not have access to a cd player * arm circumference \ 42 cm.

Keywords: hypertension high blood pressure treatment breath control breathing exercise audio cd
craniofacial microsomia: accelerating understanding of the significance and etiology

Conditions: Microtia; Microtia-Anotia; Craniofacial Microsomia; Goldenhar Syndrome; OAVS; OAV Syndrome; Hemifacial Microsomia

Summary: the cause study is a multicenter study, with domestic (n=4) and international (n=6) study sites. children and young adults (ages 0-18) who have microtia and/or craniofacial microsomia and their parents are invited to participate. children and parents are asked to provide a dna sample (blood or saliva) and are asked to upload a few photos of their face. parents are asked a short interview. participants are able to participate from home or at one of four domestic sites.


Eligibility criteria:
inclusion: cases: * participant with cfm is 0-18 years of age * participant has diagnosis of at least one of the following conditions: * microtia * anotia * facial asymmetry and preauricular tag(s) * facial asymmetry and facial tag(s) * facial asymmetry and epibulbar dermoid * facial asymmetry and macrostomia (i.e., lateral cleft) * preauricular tag and epibulbar dermoid * preauricular tag and macrostomia * facial tag and epibulbar dermoid * macrostomia and epibulbar dermoid * participant's parent or legal guardian has provided written informed consent prior to enrollment into study (for participants younger than 18 years of age). * participant speaks a language in which they are eligible for consent at their enrolling site parents: * parent participant is the biological parent of a case participant already eligible and participating in the cause study. non-genetic parents will be interviewed about their child's known prenatal and genetic family history but will not be asked to provide dna or have facial photographs taken. * participant speaks a language in which they are eligible for consent at their enrolling site other relatives: * other relatives participants, of any age, are related biologically to a case participant already eligible and participating in the cause study from a multiplex family (multiple affected individuals with cfm). * participant speaks a language in which they are eligible for consent at their enrolling site exclusion: cases: * participant is diagnosed with a known syndrome that involves microtia and underdevelopment of the jaw (townes-brocks, treacher-collins, branchiootorenal, nager, or miller syndromes). * participant has abnormal chromosome studies (karyotype). * participant has mandibular asymmetry due to deformational plagiocephaly or torticollis.
cancer-related fatigue among patients receiving home-based palliative care

Conditions: to Investigate the Level of Fatigue Among Terminal Cancer Patients Receiving Home-based Hospice Care

Summary: cancer-related fatigue, which significantly impacts the quality of life, is prevalent among patients with terminal cancer. the experiences of fatigue, its associated needs, and the strategies for managing it are closely linked to the individual uniqueness, cultural background, and resource availability of terminal cancer patients.

fatigue is defined as any perceived or actual physical or mental tiredness that adversely affects the quality of life \[7,8\]. the multifaceted nature of fatigue means it manifests in various forms, including physical cognitive, and emotional. fatigue may involve chronic exhaustion and reduced mobility that cannot be relieved by rest \[9,10\]. crf is associated with cancer progression and treatment, presenting it as a painful, persistent, and subjective sensation involving physical, emotional, and cognitive tiredness or exhaustion. crf disproportionately affects physical activities and impairs executive functions in daily life \[10,11\]. factors contributing to crf include cancer itself, treatment side effects, psychological factors such as personality traits (e.g., levels of optimism, anxiety, or depression), comorbid physical conditions, iatrogenic comorbidities, and lifestyle factors (e.g., physical activity levels) \[10-12\]. from the perspective of individual patients, fatigue frequently coexists with symptom clusters, such as insomnia, low mood or depression, or pain, collectively resulting in reduced daily functioning and diminished quality of life \[13\]. various non-pharmaceutical interventions have demonstrated effectiveness in addressing crf, including physical activity, mind-body approaches, and psychosocial interventions \[9,14,15\]. therefore, this study aims to investigate the level of fatigue among terminal cancer patients receiving home-based hospice care, hospital-based hospice care, and hospice-shared care. the anticipated results may facilitate the enhancement of crf management strategies

Eligibility criteria:
inclusion criteria: * (i) patients aged 20 years and above proficient in mandarin and/or taiwanese and willing to participate in the study; (ii) patients deemed ineligible for curative treatments by oncologists or cancer-related specialists; (iii) patients with an eastern cooperative oncology group scale (ecog) score of 2 or above suitable for hospice care; and (iv) patients who signed a letter of intent for hospice care, exclusion criteria: * preference on their national health insurance card, or signed a letter of intent for do-not-resuscitate. patients deemed too frail

Keywords: hospice care; cancer-related fatigue; eastern cooperative oncology group scale
angiogenesis markers in primiparas versus multiparas: relevance to preeclampsia incidence

Conditions: Pre-Eclampsia

Summary: the reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

primiparity is one of the main risk factors for having preeclampsia during pregnancy. recently, sflt-1, soluble fms-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. higher sflt-1 mrna, higher serum levels of sflt-1 as well as lower plgf, placental growth factor, have been found in preeclamptic patients. we intend to check the angiogenesis profile of primiparas as compared to multiparas.

Eligibility criteria:
inclusion criteria: * every delivery exclusion criteria: * preeclampsia or pregnancy induced hypertension

Keywords: preeclampsia sflt1 plgf parity angiogenesis
efficacy and tolerance evaluation of a bio-revitalizing product containing hyaluronic acid with high and low molecular weight

Conditions: Malar and Sub-malar Volume Deficiency

Summary: primary end point of the study was to evaluate clinically and by non-invasive instrumental evaluations tolerance and efficacy of a bio-revitalizing product containing hyaluronic acid with high (h-ha) and low (l-ha) molecular weight; the micro-injection of the study product was performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of healthy female volunteers aged 30-60 years. it was also aim of this study to evaluate efficacy by the volunteers and tolerance both by investigator and volunteers.


Eligibility criteria:
inclusion criteria: * female sex * age 30-60 years * agreeing to present at each study visit without make-up * accepting to not change their habits regarding food, physical activity, make-up use, face cosmetic and cleansing products * accepting not to expose their face to strong uv irradiation (uv session, or sun bathes), during the entire duration of the study, without appropriate sun protection * accepting to sign the informed consent form. exclusion criteria: * pregnancy * lactation * subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study * subjects not in menopause who do not accept to perform the pregnancy test during the basal visit, 4 and 8 weeks after the first biomineralising treatment execution * performing skin treatments for aesthetic correction (biomaterials implants, face lifting, botox injections, laser, chemical peeling) in the 12 months prior to the study start * performing permanent filler in the past * change in the normal habits regarding food, physical activity, face cosmetic, cleansing and make-up use during the month preceding the test * sensitivity to the test product or its ingredients (an accurate anamnestic assessment will performed by the investigator) * subjects whose insufficient adhesion to the study protocol is foreseeable * participation in a similar study actually or during the previous 3 months. * presence of cutaneous disease on the tested area, as lesions, scars, malformations * recurrent facial/labial herpes * clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.). * diabetes * endocrine disease * hepatic disorder * renal disorder * cardiac disorder * pulmonary disease * cancer * neurological or psychological disease * inflammatory/immunosuppressive disease * drug allergy. * anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago) * assumption of drugs able to influence the test results in the investigator opinion.
a single-centre, randomised, double-blind, controlled, parallel-group study to evaluate the effect of a fermented dairy product on abdominal distension, digestive symptoms and rectal sensitivity in patients with irritable bowel syndrome with constipation (ibs-c)

Conditions: Women With IBS-C

Summary: the purpose of this study is to evaluate the effect of a commercially available fermented dairy product containing probiotics (4 weeks, twice a day) on abdominal distension in ibs patients with constipation (ibs-c).


Eligibility criteria:
inclusion criteria: * female * age: 18-70 exclusion criteria: * na
safety and immunogenicity of the rna mcti cimatec hdt vaccine

Conditions: COVID-19; COVID-19 Vaccine

Summary: a multicenter, randomized, double-blind, active comparator, non-inferiority, multicenter iib clinical trial to compare the safety and immunogenicity of two dose levels of the mcti cimatec hdt rna vaccine against two authorized covid-19 vaccines in brazil (comirnaty - pfizer and covishield - oxford/astrazeneca) in 300 participants. each vaccine will be provided as a single booster vaccine in adults aged 18 to 65 years previously immunized with both vaccines (comirnaty - pfizer and covishield - oxford/astrazen). the investigational product mcti c hdt will be administered in one of the two doses evaluated (5µg and 10 µg). the comparator products will be comirnaty - pfizer and covishield - oxford/astrazeneca. the primary outcomes will be the number of participants with a 2-fold increase or more on average by titers of neutralizing d64g pseudovirus strain (pnt50) and comparison of titers generated by 5µg and 10µg doses of mcti-cimatec-hdt rna vaccine.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. complete primary vaccination with cominarty (pfizer) or covishield (oxford/astrazeneca) vaccines, and at least one booster dose with cominarty (pfizer) or covishield (oxford/astrazeneca) vaccines. the last duration being at least 4 before the study duration. 3. adult in a healthy condition or with a stable health status if pre-existing medical history. 4. sign informed consent, be able and willing to make the assessment, be accessible by telephone or in person by the local study team and willing to remain in the study area for the duration of the study 5. for women of childbearing age: a highly negative sensitive urinary pregnancy test during the inclusion visit and use an effective contraceptive method. exclusion criteria: 1. history of covid-19 in the 30 days before study enrollment. 2. participation in other clinical studies in the last 12 (two) months. 3. receive or plan any immunization during the study, except the seasonal influenza vaccine, within 30 days of enrollment. 4. receive a blood or immunoglobulin transfusion within 90 days before study enrollment; 5. blood donation up to 30 days before inclusion in the study; 6. chronic administration (defined as more than 14 days in total) of immunosuppressants or other immunomodulatory drugs. 7. history of autoimmune disease or immunosuppression. 8. rash, tattoos, or any other skin condition that could adversely affect the vaccine injection site. 9. body mass index (bmi) \> 35. 10. known or suspected drug or alcohol abuse in the last 6 months; 11. history of previous anaphylaxis or severe allergic reactions to the vaccine, products known to contain polyethene glycol (peg) or unknown allergens. 12. history of myocarditis or carditis.
risk of acute liver failure among patients with type 2 diabetes exposed to oral antidiabetic treatments

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to compare the incidence of hospitalization with acute liver failure among patients with type 2 diabetes who are new users of saxagliptin and those who are new users of other oral antidiabetic drugs.

prospectively designed retrospective database study. this study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice

Eligibility criteria:
inclusion criteria: * 18 years of age or older * newly prescribed saxagliptin or an oral antidiabetic drug (oad) in a class other than dipeptidyl peptidase iv (dpp4) inhibitors * enrolled in the respective database for at least 180 days prior to the first prescription of new oad * have at least one diagnostic code for a type 2 diabetes-related condition exclusion criteria: * patients identified with a diagnostic code for acute liver failure within the 180-day baseline period * patients with dpp4 inhibitor exposure during the baseline period
genetic polymorphisms predict chemotherapeutic outcomes in patients with metastatic breast cancer

Conditions: Breast Neoplasm; Drug Therapy; Polymorphism,Single Nucleotide

Summary: the investigators want to research whether genetic polymorphisms of drug-metabolizing enzymes can be used to predict chemotherapeutic outcomes in patients with metastatic breast cancer.

1. patients evaluation on all patients a complete clinical history and physical examination is performed, including routine hematology and biochemistry analyses. hematology and biochemistry analyses are repeated at the end of each cycle. toxicity is classified according to who criteria at each cycle for each patient. response is assessed after two cycles of chemotherapy and every two cycles thereafter, using response evaluation criteria in solid tumor group (recist) guidelines. 2. sample collection and snp genotyping venous blood (4 ml) is collected from each subject and placed into tubes containing edta. genomic dna is isolated with a dna blood isolation kit.genotypes are performed by pcr-rflp, pcr-dhplc and pcr-direct sequencing, etc. 3. statistical analysis x2 test is used to summarize the association of response and adverse events to chemotherapy with genetic polymorphisms.

Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic breast cancer * female * an eastern cooperative oncology group (ecog) performance status of 0-2 * at least one measurable lesion * normal cardiac, hepatic, renal and bone marrow functions * life expectancy ≥3 months * discontinuity of previous chemotherapy for a minimum of 4 weeks exclusion criteria: * central nervous system metastases * serious or uncontrolled concurrent medical illness * history of other malignancies

Keywords: breast neoplasm drug therapy polymorphism gene
evaluation of iroot sp as root canal sealer: a clinical study

Conditions: Irreversible Pulpitis; Apical Periodontitis

Summary: the purpose of this study was to evaluate the clinical and radiological outcomes of iroot sp as a root canal sealer in comparison with ah plus sealer within 1-year follow up.patients needing root canal treatment were enrolled and allotted into either iroot sp group or ah plus arm randomly. after root canal shaping and cleaning, the teeth were obturated according to their arms. assessment of postoperative pain was done 1 week after root canal obturation using visual analog scale. after 1-year follow-up, clinical and radiographic evaluations were carried out. statistical analysis at p \< 0.05 was conducted to measure difference between the arms.


Eligibility criteria:
inclusion criteria: subjects were required to: 1. have a mature tooth with closed apices; 2. have one single or multi-rooted tooth with irreversible pulpitis, pulp necrosis or apical periodontitis; 3. be prepared to appear for follow-up and 4. sign informed consent form. exclusion criteria: subjects with: 1. moderate or severe marginal periodontitis; 2. internal or external root resorption in periapical radiograph; 3. active systemic disease; 4. physical or mental disability, 5. pregnant or lactating
nutritional status in patients with chronic kidney disease

Conditions: Malnutrition

Summary: the goal of this observational study is to investigate how the glim criteria\* for the diagnosis of malnutrition should be operationalized in patients with chronic kidney disease (ckd) treated with hemodialysis. the main questions it aims to answer are: * how can malnutrition be defined when applying different combinations and operationalization strategies of the glim criteria? * how can information from other nutrition assessment tools be used in the operationalization of glim? * which combinations and operationalization strategies of the glim criteria can best predict deterioration in quality of life, muscle strength, and increased mortality? an observational study on patients with ckd in hemodialysis will be performed. variables will be extracted from the swedish renal registry, snr and medical records at two hemodialysis units at one university hospital in sweden. with start in the fall of 2024, data will be collected during two timepoints (baseline and follow-up) when wanted variables for this study are routinely measured at the units. * the global leadership initiative on malnutrition (glim) criteria to diagnose malnutrition in adults


Eligibility criteria:
inclusion criteria: * age ≥18 years * dialysis duration \&gt;3 months prior to recruitment exclusion criteria: * patients who only have a dialysis frequency of once a week * patients treated with a combination of peritoneal dialysis and hemodialysis or treated at home * patients were written consent cannot be obtained due to medical or mental illness or weakened state of health

Keywords: malnutrition muscle mass glim
training social and health care professionals in music-based therapeutic interventions to support older people with dementia

Conditions: Dementia; Older People

Summary: the study will investigate the effects of an inovative intervention based on the use of music on 45 professionals in the field of dementia, 45 elderly people with dementia.

the study aims to develop an innovative therapeutic intervention (sound intervention) based on the use of music to improve behavior, mood, well-being, and maintain cognitive function in older people with dementia. the study will investigate the effects of the sound intervention on 45 professionals in the field of dementia, 45 elderly people with dementia, and 5 family caregivers by monitoring quantitative outcome variables that will be measured through psychometric and qualitative scales interpreted through open-ended questions and observations.

Eligibility criteria:
inclusion criteria: * mild to moderate dementia * no severe hearing and visual impairment or motor problems exclusion criteria: * no formal caregiver * no informal caregiver

Keywords: dementia older people music caregiver
living with cervical cancer: assessing utilities associated with common treatment complications

Conditions: Cervical Cancer

Summary: the objective of this study is to establish patient preferences in regards to common complications of cervical cancer treatments, and to compare these preferences to those of medical providers who care for cervical cancer patients. these preferences will be determined via a interview using the standard gamble, which is a well-recognized method for establishing utilities.


Eligibility criteria:
inclusion criteria: * a subject has to have been diagnosed with early cervical cancer (stage i or ii) within the last 3 years and/or take care of patients with cervical cancer and identify her or himself as one of the following: gynecologic oncologist, radiation oncologist, physician's assistant or nurse. * subjects must be ≥18 and \<61 years old. exclusion criteria: * subjects who are unable to read and speak english proficiently will be excluded. proficiency will be assessed by the investigator enrolling patients. * subjects who do not have capacity to consent will not be included in this study. * subjects may not be investigators on this study.